Scientific Research Capability
Currently, the company has obtained clinical approval documents for children's tetravalent influenza virus subunit vaccine, adult tetravalent influenza virus subunit vaccine, and 23-valent pneumococcal polysaccharide vaccine.
The company has completed the IND registration and application of the tetravalent influenza virus subunit vaccine using its own patented technology, and obtained clinical approval documents for both adult and child dosage forms. Currently, Phase III clinical trial has been completed and NDA production approval is pending. This product covers four influenza virus strains recommended by the World Health Organization. With its high purity and good safety, it is more suitable for vaccination in children and the elderly to prevent the transmission of influenza viruses. The approval of this product also marks that China's subunit influenza vaccine is at the forefront of the world.
The 23-valent pneumococcal polysaccharide vaccine is in the phase I clinical trial stage, and the company is developing viral vaccine, bacterial vaccine, conjugate vaccine, viral recombinant subunit vaccine, and mRNA vaccine pipelines simultaneously.